Scientific Rigor. Entrepreneurial Agility.
Apogee is an early‑stage drug discovery company with a fully equipped wet laboratory in Greater Vancouver, British Columbia. We focus on some of the most challenging diseases in women’s health. By zeroing in on precise disease mechanisms and leveraging human genetics and multi‑omics data, Apogee is building and acquiring a pipeline of novel therapeutics for areas of high unmet medical need.
Apogee was founded in 2022 to acquire nearly all the assets and hire most of the scientists of a Vancouver‑based biotechnology company established in 2014 that focused on the endocannabinoid system (ECS). The acquired assets included all the intellectual property (issued and pending patents) and laboratory infrastructure. Apogee was successful in hiring the best scientists from this company and since then has recruited other top scientists.
Our leadership team brings decades of experience across pharmaceutical R&D, corporate strategy, and operations, with deep expertise in drug discovery, women’s health, immunology, the ECS, and translational science. Collectively, the team has advanced assets from target identification into the clinic across multiple programs.
Apogee fosters a culture grounded in scientific and operational excellence and an unwavering commitment to translational impact, and the ability to move insights from bench to bedside with speed and rigor.
Apogee is wholly owned a healthcare‑focused investment firm. This relationship provides resources, strategic guidance, and a long‑term horizon tailored to biomedical innovation, enabling investments in platform development, early discovery, and team expansion. Although Apogee is in the early stages of broadening our intellectual property portfolio, this strong foundation empowers us to pursue ambitious research objectives and scale with confidence.